Company intelligence / Profile preview
Ankyra Therapeutics
Cambridge, Massachusetts, United Statesankyratx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Preliminary data from the ongoing Phase 1 ANCHOR study of tolododekin alfa (ANK‑101) show that the anchored IL‑12 drug can be delivered at higher local doses than previously possible without systemic toxicity. The trial demonstrated increased CD8+ T cell infiltration and PD-L1 expression in treated tumors. Combination cohorts with checkpoint inhibitors have begun dosing patients
- Therapeutic areas
- Oncology
- Modalities
- Anchored cytokine immunotherapies (notably anchored interleukin-12)Drug conjugates
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Merck & Co.: Clinical trial collaboration to evaluate ANK–101 with KEYTRUDA® (pembrolizumab)Johnson & Johnson Lung Cancer Initiative for early clinical evaluation of ANK–101 in lung cancerJenga Biosciences licensed veterinary rights to canine version of platform/JEN–101 for animal health applications
Beyond the preview
Go deeper on Ankyra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ankyra Therapeutics.